HGF and cancer: Capmatinib is an ATP-competitive and highly selective small molecule c-MET receptor TKI that demonstrated inhibition of MET activation in cancer cells whose growth is driven by MET amplification, MET overexpression, MET exon 14 skipping mutations, and HGF-mediated activation (Baltschukat et al., 2019).